MedTrace Logo

IMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC)

NCT00351949 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2010-01-07

No results posted yet for this study

Summary

Single-center, open label, non-randomized, fixed dose-escalation, phase 1 study, performed in ambulatory and day-hospital setting

Conditions

  • Stage IV Renal Cell Carcinoma

Interventions

BIOLOGICAL

IMP321

subcutaneous injections of IMP321 every 14 days for three months (6 injections. Doses tested: 50, 250, 1,250, 6,250 or 30,000 µg

Sponsors & Collaborators

  • Umanis

    collaborator INDUSTRY

  • Immutep S.A.S.

    lead INDUSTRY

Principal Investigators

  • Bernard Escudier, M.D · Gustave Roussy, Cancer Campus, Grand Paris

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2008-08-31
Completion
2008-10-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00351949 on ClinicalTrials.gov